

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT3604511

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
HEIDI ALEXANDRA LANE	10/16/2015
FELIX BACHMANN	10/16/2015
MADLAINA BREULEUX	10/16/2015
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	BASILEA PHARMACEUTICA AG
<b>Street Address:</b>	GRENZACHERSTRASSE 487
<b>City:</b>	BASEL
<b>State/Country:</b>	SWITZERLAND
<b>Postal Code:</b>	4005
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	13980180
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(973)639-8399
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	973-596-4500
<b>Email:</b>	IPDocket@gibbonslaw.com
<b>Correspondent Name:</b>	GIBBONS P.C.
<b>Address Line 1:</b>	ONE GATEWAY CENTER
<b>Address Line 4:</b>	NEWARK, NEW JERSEY 08527
<b>ATTORNEY DOCKET NUMBER:</b>	104610-84296
<b>NAME OF SUBMITTER:</b>	ESTELLE J. TSEVDOS
<b>SIGNATURE:</b>	/ESTELLE J. TSEVDOS/
<b>DATE SIGNED:</b>	11/06/2015
<b>Total Attachments: 4</b>	
source=InventorstoBasilea#page1.tif	
source=InventorstoBasilea#page2.tif	
source=InventorstoBasilea#page3.tif	
source=InventorstoBasilea#page4.tif	

104610-84296 (22034)

ASSIGNMENT

WHEREAS, **Heidi Alexandra Lane**, Kaltbrunnenweg 8, Therwil,  
CH-4106, Switzerland; and

**Felix Bachmann**, ~~Sierenzerstrasse 16~~, Basel, CH-4055, Switzerland;

and

**Madlaina Breuleux**, Jurastrasse 52, Basel, CH-4053, Switzerland.

(Assignors) have invented certain new and useful improvements which are described and claimed in United States Patent Application No. 13/980,180, filed October 14, 2013, entitled

**USE OF BUBR1 AS A BIOMARKER OF DRUG  
RESPONSE TO FURAZANOBENZIMIDAZOLES**

which claims priority of International Patent Application Serial No.:  
PCT/EP2012/050818 filed January 9, 2012.

WHEREAS, **Basilea Pharmaceutica AG**, a corporation having its principal place of business at **Grenzacherstrasse 487, 4005 Basel, Switzerland**, is desirous of acquiring the entire interest in and to said invention, said applications and all patents to be obtained therefrom.

NOW, THEREFORE, for and in consideration of valuable consideration, the receipt and sufficiency whereof are hereby acknowledged, we have sold, assigned, and set over, and by these presents do hereby sell, assign and set over unto the said **Basilea Pharmaceutica AG** (Assignee), and said Assignee's legal representatives, successors, the entire right, title and interest, for the whole world, in and to said invention and said applications, as well as any subsequent application which claims priority based upon the filing date of any of said applications identified and the patents, both domestic and foreign, that may or shall result therefrom including the right to claim in respect of any subsequent United States and foreign patent applications and patents, the priority date of any of said applications under any United States statute and international convention or treaty; and we do hereby authorize and request the issuance of said patents, domestic and foreign, conformably to the terms of this Agreement.


UPON SAID CONSIDERATION, we do hereby covenant and agree with said Assignee that we will not execute any writing or do any act whatsoever conflicting with these presents, and that will at any time upon request, without further or additional consideration, but at the expense of the said Assignee, execute such additional assignments and other writings and so such additional acts as said Assignee may deem necessary or desirable to perfect the Assignee's enjoyment of this grant, and render all necessary assistance in making application for and obtaining provisional, original, continuation, continuation-in-part, divisional, reissued, re-examined or extended patent

#2250287 v1  
104610-84296

of the United States or of any and all foreign countries on said invention, and in enforcing any rights or chooses in action accruing as a result of such applications or patents, including but not limited to, giving testimony in any proceedings or transactions involving such applications or patents, and executing preliminary statements and other affidavits, it being understood that the foregoing covenant and agreement shall bind and inure to the benefit of the assigns and legal representatives of all parties hereto.

IN WITNESS WHEREOF, we have hereunto set our hands and affixed our seals this day of October 16, 2015.

Oct. 16, 2015  
Date

  
Heidi Alexandra Lane

Oct. 16, 2015  
Date

  
Felix Bachmann

\_\_\_\_\_  
Date

\_\_\_\_\_  
Madlaina Breuleux

104610-84296 (22034)

ASSIGNMENT

WHEREAS, **Heidi Alexandra Lane**, Kaltbrunnenweg 8, Therwil, CH-4106, Switzerland; and

**Felix Bachmann**, Sierenzerstrasse 16, Basel, CH-4055, Switzerland;

and **Madlaina Breuleux**, ~~Jurastrasse 52, Basel, CH-4050, Switzerland.~~

**213 Wallis House, Great West Road  
Brentford, TW8 0HE, UK**

16.10.2015  
HBreuleux

(Assignors) have invented certain new and useful improvements which are described and claimed in United States Patent Application No. 13/980,180, filed October 14, 2013, entitled

**USE OF BUBR1 AS A BIOMARKER OF DRUG  
RESPONSE TO FURAZANOBENZIMIDAZOLES**

which claims priority of International Patent Application Serial No.: PCT/EP2012/050818 filed January 9, 2012.

WHEREAS, **Basilea Pharmaceutica AG**, a corporation having its principal place of business at **Grenzacherstrasse 487, 4005 Basel, Switzerland**, is desirous of acquiring the entire interest in and to said invention, said applications and all patents to be obtained therefrom.

NOW, THEREFORE, for and in consideration of valuable consideration, the receipt and sufficiency whereof are hereby acknowledged, we have sold, assigned, and set over, and by these presents do hereby sell, assign and set over unto the said **Basilea Pharmaceutica AG** (Assignee), and said Assignee's legal representatives, successors, the entire right, title and interest, for the whole world, in and to said invention and said applications, as well as any subsequent application which claims priority based upon the filing date of any of said applications identified and the patents, both domestic and foreign, that may or shall result therefrom including the right to claim in respect of any subsequent United States and foreign patent applications and patents, the priority date of any of said applications under any United States statute and international convention or treaty; and we do hereby authorize and request the issuance of said patents, domestic and foreign, conformably to the terms of this Agreement.

UPON SAID CONSIDERATION, we do hereby covenant and agree with said Assignee that we will not execute any writing or do any act whatsoever conflicting with these presents, and that will at any time upon request, without further or additional consideration, but at the expense of the said Assignee, execute such additional assignments and other writings and so such additional acts as said Assignee may deem necessary or desirable to perfect the Assignee's enjoyment of this grant, and render all necessary assistance in making application for and obtaining provisional, original, continuation, continuation-in-part, divisional, reissued, re-examined or extended patent

#2250287 v1  
104610-84296

of the United States or of any and all foreign countries on said invention, and in enforcing any rights or chooses in action accruing as a result of such applications or patents, including but not limited to, giving testimony in any proceedings or transactions involving such applications or patents, and executing preliminary statements and other affidavits, it being understood that the foregoing covenant and agreement shall bind and inure to the benefit of the assigns and legal representatives of all parties hereto.

IN WITNESS WHEREOF, we have hereunto set our hands and affixed our seals this day of October 16, 2015.

\_\_\_\_\_  
Date

\_\_\_\_\_  
**Heidi Alexandra Lane**

\_\_\_\_\_  
Date

\_\_\_\_\_  
**Felix Bachmann**

16 Oct 2015

Date



\_\_\_\_\_  
**Madlaina Breuleux**

#2250287 v1  
104610-84296